ObjectiveTo investigate the clinical effect of Jiedu Liangxue Jianpi prescription in the treatment of patients with hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) in early and middle stages. MethodsA total of 75 patients who were diagnosed with HBV-ACLF in early and middle stages in Beijing Ditan Hospital from October 2017 to January 2019 were enrolled and randomly divided into integrated traditional Chinese and Western medicine group with 36 patients and control group with 39 patients. The patients in the control group were given Western medicine treatment, and those in the integrated traditional Chinese and Western medicine group were treated with Jiedu Liangxue Jianpi prescription in addition to Western medicine treatment. The course of treatment was 8 weeks for both groups. Cumulative response rate was observed for both groups, and the two groups were compared in terms of liver function, coagulation function, and routine blood test results before and after treatment. A univariate or multivariate analysis of variance with repeated measures was used for comparison between groups, and the chi-square test was used for comparison of categorical data between two groups. ResultsAt week 4 of treatment, the integrated traditional Chinese and Western medicine group had a significantly higher cumulative response rate than the control group (77.7% vs 53.8%, χ2=4.734, P＜0.05). Compared with the control group, the integrated traditional Chinese and Western medicine group had a significant increase in albumin at weeks 1 and 2 of treatment (all P＜0.05), a significant increase in prothrombin activity at week 1 of treatment (P＜0.05), and significant reductions in neutrophil count and neutrophil-lymphocyte ratio at weeks 3 and 8 of treatment (all P＜0.05). ConclusionJiedu Liangxue Jianpi prescription can improve the treatment response, liver function, and coagulation function and reduce neutrophil-lymphocyte ratio in patients with HBV-ACLF in early and middle stages.